Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7-8
|
| pubmed:dateCreated |
1984-9-20
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0361-5960
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
68
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1053-4
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6744341-Adenocarcinoma,
pubmed-meshheading:6744341-Aged,
pubmed-meshheading:6744341-Antineoplastic Agents,
pubmed-meshheading:6744341-Drug Evaluation,
pubmed-meshheading:6744341-Female,
pubmed-meshheading:6744341-Humans,
pubmed-meshheading:6744341-Male,
pubmed-meshheading:6744341-Middle Aged,
pubmed-meshheading:6744341-Pancreatic Neoplasms,
pubmed-meshheading:6744341-Pyrimethamine
|
| pubmed:articleTitle |
Phase II evaluation of metoprine in advanced pancreatic adenocarcinoma.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|